News

AgroSpheres and BASF Announce Major Strategic Partnership

AgroSpheres, a biotechnology leader in sustainable crop protection and crop health, and BASF, a global leader in agricultural solutions, are excited to announce their strategic partnership on a category defining novel bioinsecticide. This collaboration marks a significant step forward in sustainable agriculture solutions aimed at enhancing crop protection.

The companies are working together to develop biological crop protection products leveraging AgroSpheres AgriCell-powered biomolecules. Both companies are encouraged by the levels of efficacy that have been demonstrated at low dose rates to control key agricultural lepidopteran pests. Both companies are committed to working together to develop innovative and sustainable crop protection products that will increase the choices available to farmers to manage pests and support optimal productivity.

Payam Pourtaheri, CoFounder and CEO of AgroSpheres, stated, “Our partnership with BASF exemplifies the synergy that can be achieved when innovative biotech meets extensive agricultural expertise. The results of our bioinsecticide development are extremely promising, and we are eager to continue our work together to bring effective solutions to farmers worldwide.”

Ameer Shakeel, CoFounder and CTO of AgroSpheres, added, “This collaboration is a testament to our team’s ability to develop novel biomolecules, amplify them with the AgriCell and forge strategic partnerships to reach farmers around the world. We are proud to partner with BASF and are excited about the potential impact of our partnership.”

Both companies are committed to furthering their research and development efforts, with plans to accelerate the development of this product line and launch a pipeline powered by the AgriCell.

Stephanie Jensen, Vice President, Crop System Rice and Portfolio Solutions Insecticides and Seed Treatment, BASF Agricultural Solutions, concluded, “We are incredibly encouraged by the results we’ve achieved thus far and by the potential impact for our customers from this innovative technology. Moving forward, our focus remains on delivering a bioinsecticide that adds genuine value for farmers, promoting higher yields and healthier crops.”

Stefan Tresch, Head of New Technologies & BioSolutions at BASF Agricultural Solutions, remarked, “BASF is dedicated to developing innovative solutions that provide added benefit to our agricultural customers, and we believe in the unique value represented by the AgriCell platform. AgroSpheres has showcased some of the most promising biomolecules we’ve encountered. Our collaboration with AgroSpheres is a testament to the power of partnerships in driving innovation.”

Both AgroSpheres and BASF are dedicated to fostering a sustainable agricultural ecosystem, and this partnership is a crucial step in that journey.

 

Learn more here.

Recent News

01/27/2026

Higher Medicine Announces Strategic Investment by Cerdwen to Accelerate Therapies for Kabuki Syndrome and Other Brain Disorders

Higher Medicine Inc.  announced a strategic investment and fundraising partnership with Cerdwen, a venture capital firm focused on health and performance technology innovation. Based in West Chester, Pennsylvania, Cerdwen partners with visionary founders to advance transformative healthcare technologies, supporting the translation of bold scientific ideas into meaningful clinical and commercial impact. “Higher Medicine exemplifies the

01/27/2026

Epidarex Capital Announces First Close of Fund IV, Securing $145 Million to Build the Next Wave of Life Science Startups

Epidarex Capital (“Epidarex”), a transatlantic life science venture firm, today announces the first close of Epidarex Capital IV, LP, securing more than $145 million in commitments to build therapeutics and medical device companies. The Fund’s initial investors include the British Business Bank, Strathclyde Pension Fund, the Scottish National Investment Bank, as well as leading family

01/20/2026

Vibrent Health Joins a Landmark BARDA-Funded Large-Scale Hybrid/Remote Decentralized Clinical Research Study

Vibrent Health, a leading software-as-a-service (SaaS) data company in the field of precision medicine research, is collaborating with Fred Hutch Cancer Center (Fred Hutch) under a $17 million contract awarded through the Biomedical Advanced Research and Development Authority’s (BARDA) Rapid Response Partnership Vehicle (RRPV) Consortium. This collaboration drives critical research on correlates of protection (CoPs),